Turkish Ministry of Well being Grants Nationwide Reimbursement to CytoSorb®

Dr. Steiner praised the strategic collaboration with new distribution companion, Bıçakcılar Medical Devices. “Our partnership with Bıçakcılar was instrumental in acquiring nationwide reimbursement and inclusion of CytoSorb® within the healthcare catalog of the DMO. We stay up for working extra carefully with them to leverage our new reimbursement and broaden the Turkish marketplace for our merchandise.” 

Bıçakcılar Medical Gadgets is the main producer of disposable medical merchandise and OR Options in Turkey.  The corporate was established in 1959. Over time, the Bıçakcılar model has gained broad acceptance and established a convention of continued reliability and buyer satisfaction.

Dr. Souheil El Hakim, Chief Government Officer of Bıçakcılar, emphasised the vital alignment of each firms in the direction of patient-centric options which are very important to bettering scientific outcomes for critically in poor health sufferers in Turkey and past. “We consider that everybody deserves inexpensive and efficient healthcare.  In vital care drugs particularly, we’re capable of distribute the best therapies with the assistance of our in depth manufacturing services.  On the similar time, we’re working to have a direct affect on healthcare outcomes.  With CytoSorbents, we have now discovered one of the modern companions to assist us obtain this, giving us the chance to fill our method with much more life.”

Turkey supplies common well being care for roughly 95% of the nation’s 84 million residents, comparable in measurement to Germany.  There are greater than 1,500 hospitals, the place roughly 62% are public or college hospitals, and 38% are non-public.  Turkey has a big intensive care unit community, with one of many highest numbers of ICU beds per 100,000 inhabitants amongst developed nations at roughly 46, in comparison with 29 within the U.S. and 39 in Germany, for instance.  Turkey can be a central hub for medical tourism within the area, attracting 1.7 million sufferers from exterior of Turkey annually, notably for surgical procedures akin to cardiovascular, thoracic, plastic, orthopedic, and others. 

About Bıçakcılar Medical

Bıçakcılar Medical is a 60-year-old firm that has created loads of “firsts” in Turkey the place it was born. Over time, increasing globally, Bıçakcılar Medical has helped to avoid wasting lives world wide supplying the merchandise which are essential in healthcare. From medical disposables to OR Options, it stands out with two distinctive attributes: High quality management with zero tolerance for error and after gross sales service by its personal specialists, including distinctive sturdiness to its medical gear. A give attention to the “affected person” is simply one of many causes lots of its worldwide and home clients have partnered with the corporate for over 20 years. With over 800 staff and lots of enterprise companions, Bıçakcılar serves its clients by manufacturing and supplying modern, dependable and environmentally pleasant medical units. Bıçakcılar is dedicated to assuring that the whole lot it does advantages society and the surroundings whereas serving to to avoid wasting lives.

CytoSorbents Corporation is a pacesetter within the remedy of life-threatening circumstances in vital care and cardiac surgical procedure by blood purification.  Its flagship product, CytoSorb®, is permitted within the European Union and marketed in additional than 70 nations worldwide. It’s an extracorporeal cytokine adsorber designed to cut back the “cytokine storm” or “cytokine launch syndrome” that happens in widespread vital diseases and might result in large irritation, organ failure and affected person loss of life. In these illnesses, the chance of loss of life could be extraordinarily excessive, and there are few, if any, efficient remedies.  CytoSorb can be used throughout and after cardiothoracic surgical procedure to take away inflammatory mediators that may result in postoperative issues, together with a number of organ failure. As of June 30, 2022, greater than 179,000 CytoSorb units have been used cumulatively worldwide.  CytoSorb was initially launched within the European Union below the CE Mark as the primary extracorporeal cytokine adsorber. Extra CE Mark extensions have been granted for bilirubin and myoglobin removing in scientific circumstances akin to liver illness and trauma, respectively, and for ticagrelor and rivaroxaban removing throughout cardiothoracic surgical procedure.  CytoSorb has additionally acquired FDA emergency approval in the US to be used in grownup critically in poor health COVID-19 sufferers with impending or confirmed respiratory failure.  The DrugSorb™-ATR antithrombotic removing system, primarily based on the identical polymer know-how as CytoSorb, additionally acquired FDA Breakthrough Device Designation to take away ticagrelor and FDA Breakthrough Device Designation to take away the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit throughout pressing cardiothoracic procedures.  The corporate has initiated two FDA-approved pivotal research to help advertising approval of DrugSorb-ATR in the US.  The primary is the randomized, managed STAR-T (Protected and Well timed Antithrombotic Elimination-Ticagrelor) research of 120 sufferers at 30 facilities to guage whether or not intraoperative use of DrugSorb-ATR can scale back perioperative bleeding danger in ticagrelor sufferers present process cardiothoracic surgical procedure.  The second research is the STAR‑ D (Protected and Well timed Antithrombotic Elimination-Direct Oral Anticoagulants) randomized managed trial of 120 sufferers at 30 facilities evaluating the intraoperative use of DrugSorb-ATR to cut back perioperative bleeding danger in sufferers present process cardiothoracic surgical procedure who’re taking direct oral anticoagulants, together with apixaban and rivaroxaban.

CytoSorbents’ purification applied sciences are primarily based on biocompatible, extremely porous polymer beads that may actively take away poisonous substances from blood and different physique fluids by pore entrapment and floor adsorption.  The Firm’s applied sciences have acquired greater than $39.5 million in non-dilutive grants, contracts and different funding from DARPA, the U.S. Division of Well being and Human Companies (HHS), the Nationwide Institutes of Well being (NIH), the Nationwide Coronary heart, Lung, and Blood Institute (NHLBI), the U.S. Military, the U.S. Air Drive, U.S. Particular Operations Command (SOCOM), Air Drive Materials Command (USAF/AFMC) and others.  The corporate has quite a few marketed and in-development merchandise primarily based on this distinctive blood purification know-how protected by quite a few issued U.S. and worldwide patents and registered logos, in addition to a number of pending patent purposes, together with ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, Ok⁺ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb and others.  For extra info, please go to the corporate’s web sites at www.cytosorbents.com and www.cytosorb.com or comply with us on Facebook and Twitter.

Ahead-Wanting Statements

This press launch accommodates forward-looking statements that fall throughout the secure harbor of the Personal Securities Litigation Reform Act of 1995. These forward-looking statements embody, however should not restricted to, statements relating to our plans, aims, future targets and prospects for our enterprise, expectations relating to the long run affect of COVID-19 or the continuing battle between Russia and Ukraine, representations and assertions, and should not historic info and are typically recognized by means of phrases akin to “might,” “ought to,” “might,” “anticipate,” “plan,” “anticipate,” “consider,” “estimate,” “predict,” “potential,” “proceed” and comparable phrases, though some forward-looking statements are worded in a different way. You have to be conscious that the forward-looking statements on this press launch replicate administration’s present beliefs and expectations, however that our precise outcomes, occasions and efficiency might differ materially from these within the forward-looking statements. Elements that might trigger or contribute to such variations embody, however should not restricted to, the dangers disclosed in our Annual Report on Type 10-Ok filed with the SEC on March 10, 2022, our Quarterly Stories on Type 10-Q and the press releases and different communications to stockholders that we subject every so often searching for to tell events of the dangers and components which will have an effect on our enterprise. We warning you to not place undue reliance on such forward-looking statements. We’re below no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case, besides as required by federal securities legal guidelines.

Please click on to comply with us on Facebook and Twitter

U.S. Firm Contact:
Amy Vogel
305 Faculty Highway East
Princeton, NJ 08540
+1 (732) 329-8885
[email protected]

European Firm Contact:
Josephine Kraus
+49 30 765 84 66 23
[email protected]

U.S. Public Relations:
Eric Kim
Rubenstein Public Relations
212-805-3052
[email protected]

European Public Relations:
Marcus Schult
commponists
+49 69 13823 ext. 960
+49 172 4238938
[email protected]

SOURCE CytoSorbents Company